Transmitting information to us by e-mail unilaterally does not establish an attorney-client relationship or impose an obligation on either the law firm or even the receiving lawyer to keep the transmitted information confidential. By clicking "OK", you acknowledge that we have no obligation to maintain the confidentiality of any information you submit to us unless we already represent you or unless we have agreed to receive limited confidential material/information from you as a prospective client. Thus, if you are not a client or someone we have agreed to consider as a prospective client, information you submit to us by e-mail may be disclosed to others or used against you. If you would like to discuss becoming a client, please contact one of our attorneys to arrange for a meeting or telephone conference. If you wish to disclose confidential information to a lawyer in the firm before an attorney-client relationship is established, the protections that the law firm will provide to such information from a prospective client should be discussed before such information is submitted. Thank you for your interest in Goodwin Procter.

The 510(k) Program and FDA’s Initiatives

Related Content

Amneal Completes Acquisition of Kashiv

FDA Revises Draft Guidance on Substantial Evidence of Effectiveness to Clarify Confirmatory Evidence Requirements for a Single Clinical Investigation

Fresenius Kabi and Dr. Reddy’s Announce FDA Approval of Rituximab Biosimilar

FDA Issues Its First Freeze-Dried Plasma License

Jury Returns Complete Defense Verdict for Exxon and Its Officers in Securities Fraud Case

Genentech Files BPCIA Patent Infringement Suit Against Biocon Over Proposed PERJETA Biosimilar

FDA Approves Meitheal Pharmaceuticals’ Insulin Aspart Biosimilar GARZULYS

340B Drug Rebate Pilot Program Revised by HRSA

Goodwin Pharma Services Symposium

Goodwin Advises the Underwriters on Silence’s $201 Million Public Offering

Goodwin Advises Fulcrum Therapeutics on Merger with Slate Medicines and $245 Million Private Placement Financing

Goodwin Advises Zealand Pharma on Entering Into a $100 Million Royalty Purchase and Sale Agreement With Royalty Pharma for the Economics Related to rusfertide

New England Legal Awards Recognize Goodwin Partners Across Key Categories

Goodwin Represents NueCell Bio in its Launch as a New Translational Partner for Cell Therapies

Goodwin Advises QuantumCell ApS on Entering Out-Licensing and Collaboration Agreement With AlzeCure Pharma for Over $2.2 Billion

Goodwin Advises Braveheart Bio on $439.9 Million Closing of Upsized Initial Public Offering

Life Sciences